India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Skyrocketing insurance premiums and soaring rebuilding costs are transforming communities across Southwest Florida, especially in the wake of Hurricane Ian. As longtime residents struggle to keep up with rising financial pressure, wealthier newcomers and stricter building standards are reshaping the identity of places like Fort Myers Beach. With insurance rates now driving home sales, triggering potential foreclosures, and squeezing both owners and renters, Florida’s middle-class families face a growing question: can they afford to stay in the state they love?
Florida’s insurance industry is stabilizing fast, with nearly 1.6 million policies shifting from Citizens to private insurers and litigation dropping sharply. Regulators report stronger market confidence, decreasing premiums, and renewed competition—signaling one of the healthiest periods the state has seen in years.
A Leon County judge has ordered the restart of arbitration for Citizens Property Insurance claims, directly conflicting with a previous ruling that halted the process as potentially unconstitutional. With more than 400 cases now back in motion, real estate, insurance, and mortgage professionals can expect renewed activity in claim disputes and fresh uncertainty as Florida courts clash over the legality of Citizens’ arbitration system.
The DFW market is transitioning into a new construction phase marked by a slowdown in office development, a more selective approach to industrial projects, and an evolving housing landscape shaped by affordability and population growth. Developers are recalibrating their priorities, and for real estate professionals, understanding these shifts offers a critical edge in navigating—and capitalizing on—the next phase of the metroplex’s growth.
A new federal lawsuit claims Zillow pushed homebuyers toward Zillow Home Loans by rewarding affiliated agents with valuable leads — all without proper disclosure. The suit alleges undisclosed incentives, referral quotas, and potential RESPA violations, raising major concerns about steering, fiduciary duties, and Zillow’s expanding mortgage ambitions.
The mortgage industry is evolving fast, and the lenders who come out on top will be those who innovate without uprooting what already works. By building on strong technology foundations, streamlining workflows and adopting smart automation, lenders can reduce costs, improve customer experience and stay resilient in any market cycle. This article breaks down why innovation matters now, how a stable tech ecosystem protects lenders in volatile conditions and why small, strategic steps can drive long-term transformation.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
